Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Share-based Compensation (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Share-based Compensation for 14 consecutive years, with $283000.0 as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 87.42% to $283000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $649000.0 through Dec 2025, down 56.36% year-over-year, with the annual reading at $576000.0 for FY2025, 80.23% down from the prior year.
  • Share-based Compensation for Q4 2025 was $283000.0 at Aytu Biopharma, up from $114000.0 in the prior quarter.
  • The five-year high for Share-based Compensation was $3.1 million in Q4 2022, with the low at $113000.0 in Q2 2025.
  • Average Share-based Compensation over 5 years is $856263.2, with a median of $900000.0 recorded in 2023.
  • The sharpest move saw Share-based Compensation soared 233.85% in 2021, then tumbled 82.86% in 2025.
  • Over 5 years, Share-based Compensation stood at $1.2 million in 2021, then soared by 149.55% to $3.1 million in 2022, then plummeted by 73.26% to $820000.0 in 2023, then plummeted by 81.59% to $151000.0 in 2024, then surged by 87.42% to $283000.0 in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $283000.0, $114000.0, and $113000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.